Athira Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	75	92	120	487	1,113	-	-
Market Cap Growth	-	-22.89%	-75.36%	-56.26%	-	-	-
Enterprise Value	-71	-54	-79	235	929	-1	-4
PE Ratio	-0.79	-0.79	-1.25	-8.87	-55.76	-	-
PB Ratio	0.58	0.71	0.51	1.52	4.06	-	-
P/FCF Ratio	-0.92	-0.92	-1.63	-10.89	-42.09	-	-
P/OCF Ratio	-0.92	-0.92	-1.65	-11.29	-46.14	-	-
EV/EBITDA Ratio	0.46	0.46	0.83	-4.33	-46.56	0.10	0.80
EV/EBIT Ratio	0.46	0.46	0.83	-4.28	-46.55	0.10	0.80
EV/FCF Ratio	0.53	0.53	1.07	-5.26	-35.14	0.14	0.91
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.00	-0.08	-0.05
Debt / EBITDA Ratio	-0.01	-0.01	-0.02	-0.04	-0.05	-0.30	-0.14
Debt / FCF Ratio	-0.02	-0.02	-0.03	-0.04	-0.04	-0.42	-0.16
Quick Ratio	5.13	5.13	9.43	27.56	42.22	1.62	8.43
Current Ratio	5.37	5.37	9.68	28.07	43.66	1.70	8.56
Return on Equity (ROE)	-69.10%	-69.10%	-35.40%	-16.00%	-15.70%	29.80%	-
Return on Assets (ROA)	-59.90%	-59.90%	-33.60%	-15.60%	-14.20%	-144.90%	-
Return on Capital (ROIC)	-95.21%	-95.21%	-43.88%	-19.82%	-7.26%	29.99%	35.36%
Earnings Yield	-156.64%	-127.25%	-79.75%	-11.27%	-1.79%	-	-
FCF Yield	-134.53%	-109.28%	-61.38%	-9.18%	-2.38%	-	-
Buyback Yield / Dilution	-0.76%	-0.76%	-2.20%	-208.53%	-235.50%	-2.82%	-
Total Shareholder Return	-0.76%	-0.76%	-2.20%	-208.53%	-235.50%	-2.82%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).